Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2019 | Afatinib for advanced EGFRm-positive NSCLC

Antonio Passaro • 7 May 2019
ELCC 2019
Lung Cancer Non-Small Cell Lung Cancer Afatinib

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, presents interim data from a phase IIIB trial, comparing the outcomes of afatinib in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients with or without prior chemotherapy treatment. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

More from Antonio Passaro

2:04
MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib
Antonio Passaro • 22 Oct 2023
0:42
Second-generation ALK inhibitors in ALK-positive NSCLC
Antonio Passaro • 16 Apr 2019
0:44
ALK-TKIs: targeted therapies for ALK-positive NSCLC
Antonio Passaro • 16 Apr 2019

Related Videos

7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals